http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003105357-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fdaa64756184e715af6cb25ebc318917 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-122 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-136 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-235 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-136 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-235 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-122 |
| filingDate | 2002-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_958152809e9595fb2d7ce7bd62e89046 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c74896a8cc9439f969666a1a81a53d0f |
| publicationDate | 2003-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2003105357-A1 |
| titleOfInvention | Helianthrone derivatives as anti-cancer agents |
| abstract | Hypericin, helianthrone and derivatives thereof of general formula (I) n n n wherein the dotted line between positions 11 and 12 represent an optional C11-C12 bond; R is independently selected from the group consisting of hydroxy, C 1 -C 10 alkoxy, NH—C 1 -C 10 alkyl, and NH-hydroxy(C 1 -C 10 )alkyl; R′ is independently selected from the group consisting of hydroxy and C 1 -C 10 alkoxy; R″ is independently selected from the group consisting of hydrogen, hydroxy, C 1 -C 10 alkoxy, NH—C 1 -C 10 alkyl, and NH-hydroxy(C 1 -C 10 )alkyl; and R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are independently selected from the group consisting of hydrogen, hydroxy, chloro, bromo, C 1 -C 10 alkyl, C 1 -C 10 alkoxy, and C 1 -C 10 alkoxycarbonyl, provided that R″ is not hydrogen when there is a C11-C12 bond, are useful as inhibitors of angiogenesis and can be used to prevent formation of metastases and restenosis and for the treatment of angiogenesis-associated ophthalmologic disorders. In addition, the helianthrones of formula (I) can be used for the treatment of tumors in the absence of light irradiation. New compounds include those of formula I which are other than hypericin and known hypericin derivatives and there is either a C11-C12 bond or at least one R″ is other than hydrogen. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7553326-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2005113908-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8337549-B2 |
| priorityDate | 2000-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 101.